Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FDA-135 plus standard of care in early-stage COVID-19
2021-001227-41Phase 3Active
- Sponsor
- Consejo Superior de Investigaciones Científicas
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing FDA-135 plus standard of care with Standard of care alone (2 arms). Primary endpoints: Primary efficacy endpoint and Laboratory efficacy (PCR negativity). Started Oct 2021; status: active.
02
Drugs
famotidine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2021-001227-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001227-41.